GEN Exclusives

More »

GEN News Highlights

More »
Jan 9, 2012

Nanohale Acquires Scil Technology’s Development, Formulation, and Analytics Assets

  • Drug delivery technology firm Nanohale has acquired the entire R&D, contract development, and manufacturing organization of Scil Technology. The combined assets and associated workforce are part of Formycon, previously Scil’s formulation services, drug production, and analytical services company, which is now a fully owned subsidiary of Nanohale.

    Scil Technology is holding on to its tissue regeneration projects, and will continue to operate as an independent company to manage existing collaborations including its lead dental and orthopedic programs, which were outlicensed to Medtronic and Sanofi, respectively, in 2008 and 2011.

    Nanohale specializes in the development and commercialization of nanocarrier-based delivery systems for proteins and peptides, and potentially oligonucleotides such as siRNA and miRNA. The firm maintains that the acquired assets provide strong expertise in protein drug development, formulation, and analytics, as a complement to its existing protein formulation platform. “The completion of this transaction marks a significant broadening of the product and service portfolio of the Nanohale group, and will facilitate the further transition from a pure technology-based company into a globally operating specialty pharma company,” remarks Nicolas Combé, Ph.D., CFO.

    Biopharmaceutical development and formulations firm Scil says the transaction provides an ideal exit opportunity for its investors. “We have chosen Nanohale as a partner because of its perfect fit and the strategic concept of the company,” notes Christian Nafe, Scil CEO. “Nanohale will be able to make optimum use of Scil Technology’s expertise and platform for both internal drug development and external R&D services.”


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?